rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-545-553rsp-3410Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESРитуксимаб в лечении болезни Грейвса и эндокринной офтальмопатии. Возможности и ограниченияRituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitationshttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

115522, Москва, Каширское шоссе, 34а;680000, Хабаровск, ул. Муравьева-Амурского, 35

115522, Moscow, Kashirskoye Highway, 34A;680000, Khabarovsk, Muravyova-Amurskogo str., 35

tarasel@list.ruhttps://orcid.org/0000-0002-4579-2836ЗоткинЕ. Г.ZotkinE. G.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

ezotkin@mail.ruhttps://orcid.org/0000-0002-8520-8702ТрошинаЕ. А.TroshinaE. A.

117036, Москва, ул. Дм. Ульянова, 11

117036, Moscow, Dm. Ulyanova str., 11

troshina@inbox.ruhttps://orcid.org/0000-0001-7958-5926ЛукинаГ. В.LukinaG. V.

115522, Москва, Каширское шоссе, 34а;111123, Москва, шоссе Энтузиастов, 86

115522, Moscow, Kashirskoye Highway, 34A;111123, Moscow, Entuziastov Highway, 86

gvl3@yandex.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Far Eastern State Medical UniversityRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииРоссияNational Medical Research Center for EndocrinologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ГБУЗ «Московский клинический научный центр им. А.С. Логинова Департамента здравоохранения города Москвы»РоссияV.A. Nasonova Research Institute of Rheumatology; Loginov Moscow Clinical Scientific CenterRussian Federation202327102023615545553Copyright © Паневин Т.С., Зоткин Е.Г., Трошина Е.А., Лукина Г.В., 20232023Паневин Т.С., Зоткин Е.Г., Трошина Е.А., Лукина Г.В.Panevin T.S., Zotkin E.G., Troshina E.A., Lukina G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3410

Ритуксимаб (РТМ) представляет собой химерное (мышиное и человеческое) моноклональное антитело к B-лимфоцитами (CD20). Данный препарат широко применяется в ревматологии при лечении ревматоидного артрита, синдрома Шегрена, некоторых системных заболеваний соединительной ткани и васкулитов, а также в гематологии при лимфопролиферативных заболеваниях. Введение РТМ приводит к деплеции B-лимфоцитов через различные механизмы, включая антителозависимый и комплемент-зависимый цитотоксический эффекты, а также регуляцию апоптоза. Учитывая механизм аутоиммунного повреждения при болезни Грейвса – аутоимммунном заболевании щитовидной железы, сопровождающимся тиреотоксикозом и эндокринной офтальмопатией (аутоиммунным поражением вспомогательного аппарата глаза), – применение РТМ может быть эффективным при данных заболеваниях. В обзоре рассмотрены имеющиеся на сегодняшний день результаты исследований применения различных доз РТМ при данных заболеваниях.

Rituximab is a chimeric (mouse and human) monoclonal antibody against B-lymphocytes (CD20). This drug is widely used in rheumatology in the treatment of rheumatoid arthritis, Sjogren’s syndrome, some systemic connective tissue diseases and vasculitis, as well as in hematology in lymphoproliferative diseases. Administration of rituximab leads to depletion of B-lymphocytes through various mechanisms, including antibody-dependent and complementdependent cytotoxic effects, as well as the regulation of apoptosis. Considering the mechanism of autoimmune damage in Graves’ disease, an autoimmune thyroid disease accompanied by thyrotoxicosis and endocrine ophthalmopathy (an autoimmune lesion of the accessory apparatus of the eye), the use of rituximab may be effective in these diseases. The review considers the currently available results of studies on the use of various doses of rituximab in these diseases.

ритуксимабболезнь Грейвсадиффузный токсический зобэндокринная офтальмопатияrituximabGraves’ diseasediffuse toxic goiterendocrine ophthalmopathyReferencesBahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8): 726-738. doi: 10.1056/NEJMra0905750Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8): 726-738. doi: 10.1056/NEJMra0905750Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves’ ophthalmopathy: Epidemiology and natural history. Intern Med. 2014;53(5):353-360. doi: 10.2169/internalmedicine.53.1518Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves’ ophthalmopathy: Epidemiology and natural history. Intern Med. 2014;53(5):353-360. doi: 10.2169/internalmedicine.53.1518Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98(4):1443-1449. doi: 10.1210/jc.2012-3873Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98(4):1443-1449. doi: 10.1210/jc.2012-3873Soroudi AE, Goldberg RA, McCann JD. Prevalence of asymmetric exophthalmos in Graves orbitopathy. Ophthalmic Plast Reconstr Surg. 2004;20(3):224-225. doi: 10.1097/01.iop.0000124675.80763.5aSoroudi AE, Goldberg RA, McCann JD. Prevalence of asymmetric exophthalmos in Graves orbitopathy. Ophthalmic Plast Reconstr Surg. 2004;20(3):224-225. doi: 10.1097/01.iop.0000124675.80763.5aBartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993. doi: 10.3389/fendo.2020.615993Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993. doi: 10.3389/fendo.2020.615993Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al.; EUGOGO. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. doi: 10.1530/EJE-21-0479Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al.; EUGOGO. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. doi: 10.1530/EJE-21-0479Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177-185. doi: 10.1097/WNO.0000000000000132Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177-185. doi: 10.1097/WNO.0000000000000132Mysliwiec J, Palyga I, Kosciuszko M, Kowalska A, Gorska M. Circulating CXCL9 and CXCL10 as markers of activity of Graves’ orbitopathy during treatment with corticosteroids and teleradiotherapy. Horm Metab Res. 2012;44(13):957-961. doi: 10.1055/s-0032-1316352Mysliwiec J, Palyga I, Kosciuszko M, Kowalska A, Gorska M. Circulating CXCL9 and CXCL10 as markers of activity of Graves’ orbitopathy during treatment with corticosteroids and teleradiotherapy. Horm Metab Res. 2012;44(13):957-961. doi: 10.1055/s-0032-1316352Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, et al. Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101388. doi: 10.1016/j.beem.2020.101388Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, et al. Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101388. doi: 10.1016/j.beem.2020.101388Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant. 2006;6(5 Pt 1):859-866. doi: 10.1111/j.1600-6143.2006.01288.xPescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant. 2006;6(5 Pt 1):859-866. doi: 10.1111/j.1600-6143.2006.01288.xАнаньева ЛП, Соловьев СК, Бекетова ТВ, Васильев ВИ, Антелава ОА, Александрова ЕН, и др. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495-506. doi: 10.14412/1995-4484-2014-495-506Ananieva LP, Soloviyov SK, Beketova TV, Vasiliev VI, Antelava OA, Aleksandrova EN, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: Efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(5):495-506 (In Russ.). doi: 10.14412/1995-4484-2014-495-506Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57(Прил 1):3-40 doi: 10.14412/1995-4484-2019-3-40Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(Suppl 1):3-40 (In Russ.). doi: 10.14412/1995-4484-2019-3-40Насонов ЕЛ. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5): 539-548. doi: 10.14412/1995-4484-2018-539-548Nasonov EL. Prospects for anti-B-cell therapy in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(5):539-548 (In Russ.). doi: 10.14412/1995-4484-2018-539-548Насонов ЕЛ, Мазуров ВИ, Усачева ЮВ, Черняева ЕВ, Устюгов ЯЮ, Улитин АБ, и др. Разработки отечественных оригинальных генно-инженерных биологических препаратов для лечения иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2017;55(2):201-210. doi: 10.14412/1995-4484-2017-201-210Nasonov EL, Mazurov VI, Usacheva YuV, Chernyaeva EV, Ustyugov YYu, Ulitin AB, et al. Developments of russian original biological agents for the treatment of immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(2):201-210 (In Russ.). doi: 10.14412/1995-4484-2017-201-210Насонов ЕЛ, Мазуров ВИ, Зонова ЕВ, Князева ЛА, Марусенко ИМ, Несмеянова ОБ, и др. Эффективность и безопасность биоаналога ритуксимаба (Ацеллбия) при ревматоидном артрите в качестве «первого» генно-инженерного биологического препарата: результаты клинического исследования III фазы (ALTERRA). Научно-практическая ревматология. 2017;55(4):351-359. doi: 10.14412/1995-4484-2017-351-359Nasonov EL, Mazurov VI, Zonova EV, Knyazeva LA, Marusenko IM, Nesmeyanova OB, et al. The efficacy and safety of rituximab biosimilar (Acellbia®) in rheumatoid arthritis as the first biological agent: Results of phase III (alterra) clinical trial. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(4):351-359 (In Russ.). doi: 10.14412/1995-4484-2017-351-359Насонов ЕЛ, Зонова ЕВ, Иванова ОН, Князева ЛА, Мазуров ВИ, Самигуллина РР, и др. Результаты сравнительного клинического исследования III фазы препаратов ритуксимаба (Ацеллбия и Мабтера) при ревматоидном артрите (исследование BIORA). Научно-практическая ревматология. 2016;54(5): 510-519. doi: 10.14412/1995-4484-2016-510-519Nasonov EL, Zonova EV, Ivanova ON, Knyazeva LA, Mazurov VI, Samigullina RR, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and Mabthera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(5):510-519 (In Russ.). doi: 10.14412/1995-4484-2016-510-519Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 “what do B-cells do?”. Clin Immunol. 2005;117(3):207-213. doi: 10.1016/j.clim.2005.08.006Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 “what do B-cells do?”. Clin Immunol. 2005;117(3):207-213. doi: 10.1016/j.clim.2005.08.006Hasselbalch HC. B-cell depletion with rituximab-a targeted therapy for Graves’ disease and autoimmune thyroiditis. Immunol Lett. 2003;88(1):85-86. doi: 10.1016/s0165-2478(03)00032-4Hasselbalch HC. B-cell depletion with rituximab-a targeted therapy for Graves’ disease and autoimmune thyroiditis. Immunol Lett. 2003;88(1):85-86. doi: 10.1016/s0165-2478(03)00032-4Паневин ТС, Молашенко НВ, Трошина ЕА, Головенко ЕН. Аутоиммунный полигландулярный синдром взрослых: современные представления о предикторах развития поражения миокарда и диагностике компонентов заболевания. Клиническая и экспериментальная тиреоидология. 2018;14(2):92-99. doi: 10.14341/ket9641Panevin TS, Molashenko NV, Troshina EA, Golovenko EN. Autoimmune polyglandular syndrome of adults: Current ideas about predictors development of damage of a myocardium and diagnostics of components of a disease. Clinical and Experimental Thyroidology. 2018;14(2):92-99 (In Russ.). doi: 10.14341/ket9641Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, et al. The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019;18(3):287-292. doi: 10.1016/j.autrev.2018.10.001Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, et al. The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019;18(3):287-292. doi: 10.1016/j.autrev.2018.10.001El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol. 2006;154(5):623-632. doi: 10.1530/eje.1.02140El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol. 2006;154(5):623-632. doi: 10.1530/eje.1.02140El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: A controlled pilot study. J Clin Endocrinol Metab. 2007;92(5):1769-1772. doi: 10.1210/jc.2006-2388El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: A controlled pilot study. J Clin Endocrinol Metab. 2007;92(5):1769-1772. doi: 10.1210/jc.2006-2388Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, et al. Rituximab in relapsing Graves’ disease, a phase II study. Eur J Endocrinol. 2008;159(5):609-615. doi: 10.1530/EJE-08-0084.Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, et al. Rituximab in relapsing Graves’ disease, a phase II study. Eur J Endocrinol. 2008;159(5):609-615. doi: 10.1530/EJE-08-0084.Cheetham TD, Cole M, Abinun M, Allahabadia A, Barratt T, Davies JH, et al. Adjuvant rituximab-exploratory trial in young people with Graves disease. J Clin Endocrinol Metab. 2022;107(3):743-754. doi: 10.1210/clinem/dgab763Cheetham TD, Cole M, Abinun M, Allahabadia A, Barratt T, Davies JH, et al. Adjuvant rituximab-exploratory trial in young people with Graves disease. J Clin Endocrinol Metab. 2022;107(3):743-754. doi: 10.1210/clinem/dgab763Jang SY, Shin DY, Lee EJ, Choi YJ, Lee SY, Yoon JS. Correlation between TSH receptor antibody assays and clinical manifestations of Graves’ orbitopathy. Yonsei Med J. 2013;54(4):1033-1039. doi: 10.3349/ymj.2013.54.4.1033Jang SY, Shin DY, Lee EJ, Choi YJ, Lee SY, Yoon JS. Correlation between TSH receptor antibody assays and clinical manifestations of Graves’ orbitopathy. Yonsei Med J. 2013;54(4):1033-1039. doi: 10.3349/ymj.2013.54.4.1033Mishra S, Maurya VK, Kumar S, Ankita, Kaur A, Saxena SK. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: Current and future perspectives. Curr Eye Res. 2020;45(11):1325-1341. doi: 10.1080/02713683.2020.1776331Mishra S, Maurya VK, Kumar S, Ankita, Kaur A, Saxena SK. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: Current and future perspectives. Curr Eye Res. 2020;45(11):1325-1341. doi: 10.1080/02713683.2020.1776331Karasek D, Cibickova L, Karhanova M, Kalitova J, Schovanek J, Frysak Z. Clinical and immunological changes in patients with active moderate-to-severe Graves’ orbitopathy treated with very low-dose rituximab. Endokrynol Pol. 2017;68(5):498-504. doi: 10.5603/EP.a2017.0040Karasek D, Cibickova L, Karhanova M, Kalitova J, Schovanek J, Frysak Z. Clinical and immunological changes in patients with active moderate-to-severe Graves’ orbitopathy treated with very low-dose rituximab. Endokrynol Pol. 2017;68(5):498-504. doi: 10.5603/EP.a2017.0040El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009;130(3):252-258. doi: 10.1016/j.clim.2008.09.007El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009;130(3):252-258. doi: 10.1016/j.clim.2008.09.007Supronik J, Szelachowska M, Kretowski A, Siewko K. Rituximab in the treatment of Graves’ orbitopathy: Latest updates and perspectives. Endocr Connect. 2022;11(12):e220303. doi: 10.1530/EC-22-0303Supronik J, Szelachowska M, Kretowski A, Siewko K. Rituximab in the treatment of Graves’ orbitopathy: Latest updates and perspectives. Endocr Connect. 2022;11(12):e220303. doi: 10.1530/EC-22-0303Vannucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Currò N, et al. Rituximab treatment in patients with active Graves’ orbitopathy: Effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010;161(3):436-443. doi: 10.1111/j.1365-2249.2010.04191.xVannucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Currò N, et al. Rituximab treatment in patients with active Graves’ orbitopathy: Effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010;161(3):436-443. doi: 10.1111/j.1365-2249.2010.04191.xChen J, Chen G, Sun H. Intravenous rituximab therapy for active Graves’ ophthalmopathy: A meta-analysis. Hormones (Athens). 2021;20(2):279-286. doi: 10.1007/s42000-021-00282-6Chen J, Chen G, Sun H. Intravenous rituximab therapy for active Graves’ ophthalmopathy: A meta-analysis. Hormones (Athens). 2021;20(2):279-286. doi: 10.1007/s42000-021-00282-6Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422-431. doi: 10.1210/jc.2014-3014Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422-431. doi: 10.1210/jc.2014-3014Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432-441. doi: 10.1210/jc.2014-2572Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432-441. doi: 10.1210/jc.2014-2572Stan MN, Salvi M. Management of endocrine disease: Rituximab therapy for Graves’ orbitopathy – Lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):101-109. doi: 10.1530/EJE-16-0552Stan MN, Salvi M. Management of endocrine disease: Rituximab therapy for Graves’ orbitopathy – Lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):101-109. doi: 10.1530/EJE-16-0552Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79(2):145-151. doi: 10.1111/cen.12222Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79(2):145-151. doi: 10.1111/cen.12222Eid L, Coste-Verdier V, Longueville E, Ribeiro E, NicolescuCatargi B, Korobelnik JF. The effects of rituximab on Graves’ orbitopathy: A retrospective study of 14 patients. Eur J Ophthalmol. 2020;30(5):1008-1013. doi: 10.1177/1120672119845224Eid L, Coste-Verdier V, Longueville E, Ribeiro E, NicolescuCatargi B, Korobelnik JF. The effects of rituximab on Graves’ orbitopathy: A retrospective study of 14 patients. Eur J Ophthalmol. 2020;30(5):1008-1013. doi: 10.1177/1120672119845224Deltour JB, d’Assigny Flamen M, Ladsous M, Giovansili L, Cariou B, Caron P, et al. Efficacy of rituximab in patients with Graves’ orbitopathy: A retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol. 2020;258(9):2013-2021. doi: 10.1007/s00417-020-04651-6Deltour JB, d’Assigny Flamen M, Ladsous M, Giovansili L, Cariou B, Caron P, et al. Efficacy of rituximab in patients with Graves’ orbitopathy: A retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol. 2020;258(9):2013-2021. doi: 10.1007/s00417-020-04651-6Bennedjaï A, Bouheraoua N, Gatfossé M, Dupasquier-Fediaevsky L, Errera MH, Tazartes M, et al. Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves’ orbitopathy. Ocul Immunol Inflamm. 2022;30(2):500-505. doi: 10.1080/09273948.2020.1808688Bennedjaï A, Bouheraoua N, Gatfossé M, Dupasquier-Fediaevsky L, Errera MH, Tazartes M, et al. Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves’ orbitopathy. Ocul Immunol Inflamm. 2022;30(2):500-505. doi: 10.1080/09273948.2020.1808688Vannucchi G, Campi I, Covelli D, Currò N, Lazzaroni E, Palomba A, et al. Efficacy profile and safety of very low-dose rituximab in patients with Graves’ orbitopathy. Thyroid. 2021;31(5):821-828. doi: 10.1089/thy.2020.0269Vannucchi G, Campi I, Covelli D, Currò N, Lazzaroni E, Palomba A, et al. Efficacy profile and safety of very low-dose rituximab in patients with Graves’ orbitopathy. Thyroid. 2021;31(5):821-828. doi: 10.1089/thy.2020.0269Wang Y, Hu H, Chen L, Zhang H, Yang T, Xu X, et al. Observation study of using a small dose of rituximab treatment for thyroidassociated ophthalmopathy in seven Chinese patients: One pilot study. Front Endocrinol (Lausanne). 2023;13:1079852. doi: 10.3389/fendo.2022.1079852Wang Y, Hu H, Chen L, Zhang H, Yang T, Xu X, et al. Observation study of using a small dose of rituximab treatment for thyroidassociated ophthalmopathy in seven Chinese patients: One pilot study. Front Endocrinol (Lausanne). 2023;13:1079852. doi: 10.3389/fendo.2022.1079852Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves’ disease. J Clin Endocrinol Metab. 1996;81(8):2976-2979. doi: 10.1210/jcem.81.8.8768861Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves’ disease. J Clin Endocrinol Metab. 1996;81(8):2976-2979. doi: 10.1210/jcem.81.8.8768861Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98(11):4291-4299. doi: 10.1210/jc.2013-1804Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98(11):4291-4299. doi: 10.1210/jc.2013-1804van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-1502. doi: 10.1136/annrheumdis-2012-201956van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-1502. doi: 10.1136/annrheumdis-2012-201956Varley CD, Winthrop KL. Long-term safety of rituximab (risks of viral and opportunistic infections). Curr Rheumatol Rep. 2021;23(9):74. doi: 10.1007/s11926-021-01037-3Varley CD, Winthrop KL. Long-term safety of rituximab (risks of viral and opportunistic infections). Curr Rheumatol Rep. 2021;23(9):74. doi: 10.1007/s11926-021-01037-3van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558-567. doi: 10.3899/jrheum.090856van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558-567. doi: 10.3899/jrheum.090856Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P, et al. Small dose of rituximab for graves orbitopathy: New insights into the mechanism of action. Arch Ophthalmol. 2012;130(1):122-124. doi: 10.1001/archopthalmol.2011.1215Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P, et al. Small dose of rituximab for graves orbitopathy: New insights into the mechanism of action. Arch Ophthalmol. 2012;130(1):122-124. doi: 10.1001/archopthalmol.2011.1215Campi I, Vannucchi G, Muller I, Lazzaroni E, Currò N, Dainese M, et al. Therapy with different dose regimens of rituximab in patients with active moderate-to-severe Graves’ orbitopathy. Front Endocrinol (Lausanne). 2022;12:790246. doi: 10.3389/fendo.2021.790246Campi I, Vannucchi G, Muller I, Lazzaroni E, Currò N, Dainese M, et al. Therapy with different dose regimens of rituximab in patients with active moderate-to-severe Graves’ orbitopathy. Front Endocrinol (Lausanne). 2022;12:790246. doi: 10.3389/fendo.2021.790246Bartalena L, Wiersinga WM. Proposal for standardization of primary and secondary outcomes in patients with active, moderateto-severe Graves’ orbitopathy. Eur Thyroid J. 2020;9(Suppl 1):3-16. doi: 10.1159/000510700Bartalena L, Wiersinga WM. Proposal for standardization of primary and secondary outcomes in patients with active, moderateto-severe Graves’ orbitopathy. Eur Thyroid J. 2020;9(Suppl 1):3-16. doi: 10.1159/000510700Насонов ЕЛ, Авдеева АС. Деплеция В-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (COVID-19). Научно-практическая ревматология. 2021;59(4):384-393. doi: 10.47360/1995-4484-2021-384-393Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):384-393 (In Russ.). doi: 10.47360/1995-4484-2021-384-393Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al.; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-1400. doi: 10.1002/art.21778Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al.; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-1400. doi: 10.1002/art.21778Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581. doi: 10.1056/NEJMoa032534Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581. doi: 10.1056/NEJMoa032534Higashida J, Wun T, Schmidt S. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor – A treatment. Rheumatology. 2005;32:2109-2115.Higashida J, Wun T, Schmidt S. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor – A treatment. Rheumatology. 2005;32:2109-2115.Авдеева АС, Кусевич ДА. Роль лабораторных биомаркеров в прогнозировании эффективности терапии ритуксимабом при ревматоидном артрите (новые данные). Научно-практическая ревматология. 2017;55(3):295-303. doi: 10.14412/1995-4484-2017-295-303Avdeeva AS, Kusevich DA. The role of laboratory biomarkers in predicting the efficiency of rituximab therapy for rheumatoid arthritis: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(3):295-303 (In Russ.). doi: 10.14412/1995-4484-2017-295-303Авдеева АС, Черкасова МВ, Кусевич ДА, Рыбакова ВВ, Насонов ЕЛ. Сравнение клинико-иммунологических эффектов оригинального ритуксимаба (Мабтера) и его биоаналога (Ацеллбия) у больных ревматоидным артритом. Клиническая фармакология и терапия. 2019;28(4):30-36. doi: 10.32756/0869-5490-2019-4-30-36Avdeeva AS, Cherkasova MB, Kusevich DA, Rybakova VV, Nasonov EL. Clinical and immunological effects of the original and biosimilar rituximab in patients with rheumatoid arthritis. Clinical Pharmacology and Therapy. 2019;28(4):30-36 (In Russ.). doi: 10.32756/0869-5490-2019-4-30-36Hu Y, Chen J, Lin K, Yu X. Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves’ ophthalmopathy: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1160936. doi: 10.3389/fendo.2023.1160936Hu Y, Chen J, Lin K, Yu X. Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves’ ophthalmopathy: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1160936. doi: 10.3389/fendo.2023.1160936Bartalena L, Tanda ML. Current concepts regarding Graves’ orbitopathy. J Intern Med. 2022;292(5):692-716. doi: 10.1111/joim.13524Bartalena L, Tanda ML. Current concepts regarding Graves’ orbitopathy. J Intern Med. 2022;292(5):692-716. doi: 10.1111/joim.13524Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. doi: 10.1056/NEJMoa1910434Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. doi: 10.1056/NEJMoa1910434Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761. doi: 10.1056/NEJMoa1614949Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761. doi: 10.1056/NEJMoa1614949Bartalena L, Marinò M, Marcocci C, Tanda ML. Teprotumumab for Graves’ orbitopathy and ototoxicity: Moving problems from eyes to ears? J Endocrinol Invest. 2022;45(7):1455-1457. doi: 10.1007/s40618-022-01791-wBartalena L, Marinò M, Marcocci C, Tanda ML. Teprotumumab for Graves’ orbitopathy and ototoxicity: Moving problems from eyes to ears? J Endocrinol Invest. 2022;45(7):1455-1457. doi: 10.1007/s40618-022-01791-w

The authors declare that there are no conflicts of interest present.